GlassScriptPhysician profile
Ankush Ratwani
NPI 1437511664
$6,722.96
in general payments reported to CMS, 2019-2025
15 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $233 · 2024: $5,112 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $2,144 · Food and Beverage: $1,346 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $2,144.42 |
| Food and Beverage | $1,345.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,637.15 | 2024-2025 | |
| Medtronic, INC. | $995.53 | 2024 | Illumisite |
| Steris Corporation | $321.74 | 2022-2025 | |
| Noah Medical Corporation | $270.10 | 2025 | Galaxy |
| Olympus America INC. | $109.04 | 2024-2025 | Single-Use Flexible Video Bronchoscope |
| Pulmonx Corporation | $99.38 | 2024-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Merck Sharp & Dohme LLC | $67.51 | 2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $41.88 | 2025 | Dupixent |
| Grifols USA, LLC | $31.27 | 2025 | Prolastin-C Liquid |
| Electromed, INC. | $28.10 | 2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $28.07 | 2025 | Fasenra, Airsupra |
| Jazz Pharmaceuticals INC. | $25.14 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.36 | 2025 | Glassia |
| Insmed, INC. | $22.86 | 2025 | Arikayce |
| Baxter Healthcare | $20.83 | 2025 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankush Ratwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.